Copenhagen’s Biograil raises €20 million for oral drug delivery device designed as an alternative to injections
Biograil, a Copenhagen-based BioTech company developing an oral device to deliver therapeutics that would otherwise require injection, has closed a €20 million funding round. The round was backed by Verve Ventures and Megatrend Invest. HTGF, which led the company’s Seed syndicate in 2019, participat
<p>Biograil, a Copenhagen-based BioTech company developing an oral device to deliver therapeutics that would otherwise require injection, has closed a €20 million funding round. The round was backed by Verve Ventures and Megatrend Invest. HTGF, which led the company’s Seed syndicate in 2019, participat</p>